医疗技术小组报告,Q3的利润率达到52%,达到986 308美元。 Regenerative Medical Technology Group reports Q3 profitability with sales up 52% to $986,308.

恢复医疗技术小组(RMTG)报告,在Q3 2024年,业务利润率达到52%,比上一年增长52%,达到986 308美元,总利润率为75%。 Regenerative Medical Technology Group (RMTG) reported operational profitability in Q3 2024, with sales up 52% from the previous year to $986,308, and a gross profit margin of 75%. 收入剧增主要是由于病人的手术程序增加了37%。 The surge in revenue is largely due to a 370% increase in patient procedures. RMTG计划扩大规模,开设新的诊所,建立生物学制造设施,以进一步提高利润和产品质量。 RMTG plans to expand by opening new clinics and building a manufacturing facility for biologics to further enhance margins and product quality.